National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 626-635

  Önnestam, Lisa ^a   Berinder, Katarina ^b   Burman, Pia ^c   Dahlqvist, Per ^d   Engström, Britt Edén ^e   Wahlberg, Jeanette ^f   Nyström, Helena Filipsson ^g  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN DERIVATIVE; THYROTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CORTICOTROPIN DEFICIENCY; ENDOCRINE SURGERY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HORMONE DETERMINATION; HUMAN; HYPERTHYROIDISM; HYPOPITUITARISM; HYPOTHYROIDISM; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SEX DIFFERENCE; SWEDEN; THYROTROPIN SECRETING ADENOMA; UNIVERSITY HOSPITAL;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREVALENCE; REGISTRIES; SWEDEN; THYROID HORMONES; THYROTROPIN; TREATMENT OUTCOME;

EID: 84873640201     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3362     Document Type: Article

References (24)

1. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007;156:203-216.
2. Raappana A, Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010;95:4268-4275.
3. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377-382.
4. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769-4775.
5. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610-638.
6. Bertholon-Gregoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J. Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol. 1999;140:519-527.
7. Hay ID, Klee GG. Linking medical needs and performance goals: clinical and laboratory perspectives on thyroid disease. Clin Chem. 1993;39:1519-1524.
8. Caldwell G, Kellett HA, Gow SM, et al. A new strategy for thyroid function testing. Lancet. 1985;1:1117-1119.
9. Ross DS, Ardisson LJ, Meskell MJ. Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay. J Clin Endocrinol Metab. 1989;69:684-688.
10. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148:433-442.
11. Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23:597-606.
12. Weiss RE, Refetoff S. Resistance to thyroid hormone. Rev Endocr Metab Disord. 2000;1:97-108.
13. Wynne AG, Gharib H, Scheithauer BW, Davis DH, Freeman SL, Horvath E. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med. 1992;92:15-24.
14. Despres N, Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem. 1998;44:440-454.
15. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994; 120:817-820.
16. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999;84:476-486.
17. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab. 2000;85:1420-1425.
18. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf). 1994;41:359-364.
19. Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006;154:753-758.
20. Steinmaus C, Miller MD, Howd R. Impact of smoking and thiocyanate on perchlorate and thyroid hormone associations in the 2001-2002 national health and nutrition examination survey. Environ Health Perspect. 2007;115:1333-1338.
21. Wang EL, Qian ZR, Yamada S, et al. Clinicopathological characterization of TSH-producing adenomas: special reference to TSHimmunoreactive but clinically non-functioning adenomas. Endocr Pathol. 2009;20:209-220.
22. Sanno N, Teramoto A, Osamura RY. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg. 2000;93:194-200.
23. Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000;85:1487-1491.
24. Gatto F, Barbieri F, Castelletti L, et al. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary. 2011;14:141-147.